financetom
Business
financetom
/
Business
/
Looking At Lam Research's Recent Unusual Options Activity
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Looking At Lam Research's Recent Unusual Options Activity
Nov 29, 2024 8:59 AM

Whales with a lot of money to spend have taken a noticeably bullish stance on Lam Research ( LRCX ).

Looking at options history for Lam Research ( LRCX ) we detected 17 trades.

If we consider the specifics of each trade, it is accurate to state that 70% of the investors opened trades with bullish expectations and 17% with bearish.

From the overall spotted trades, 9 are puts, for a total amount of $453,104 and 8, calls, for a total amount of $321,700.

Expected Price Movements

Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $55.0 to $104.0 for Lam Research ( LRCX ) over the last 3 months.

Insights into Volume & Open Interest

In today's trading context, the average open interest for options of Lam Research ( LRCX ) stands at 1634.3, with a total volume reaching 6,030.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Lam Research ( LRCX ), situated within the strike price corridor from $55.0 to $104.0, throughout the last 30 days.

Lam Research 30-Day Option Volume & Interest Snapshot

Biggest Options Spotted:

Symbol PUT/CALL Trade Type Sentiment Exp. Date Ask Bid Price Strike Price Total Trade Price Open Interest Volume
LRCX PUT SWEEP BULLISH 01/16/26 $3.4 $3.35 $3.35 $55.00 $100.6K 1.5K 300
LRCX PUT SWEEP NEUTRAL 06/20/25 $2.58 $2.5 $2.5 $60.00 $75.0K 681 300
LRCX PUT SWEEP BULLISH 06/20/25 $7.2 $6.8 $6.9 $72.00 $51.7K 690 962
LRCX PUT TRADE BULLISH 12/06/24 $10.0 $9.55 $9.62 $85.00 $48.0K 0 150
LRCX CALL TRADE BEARISH 01/15/27 $25.3 $23.1 $23.1 $70.00 $46.2K 137 20

About Lam Research

Lam Research ( LRCX ) is one of the largest semiconductor wafer fabrication equipment manufacturers in the world. It specializes in deposition and etch, which entail the buildup of layers on a semiconductor and the subsequent selective removal of patterns from each layer. Lam holds the top market share in etch and holds the clear second share in deposition. It is more exposed to memory chipmakers for DRAM and NAND chips. It counts as top customers the largest chipmakers in the world, including TSMC, Samsung, Intel, and Micron.

Current Position of Lam Research

Trading volume stands at 4,175,509, with LRCX's price up by 5.38%, positioned at $75.42.

RSI indicators show the stock to be may be approaching overbought.

Earnings announcement expected in 54 days.

What The Experts Say On Lam Research

In the last month, 1 experts released ratings on this stock with an average target price of $85.0.

Unusual Options Activity Detected: Smart Money on the Move

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. Click here for access.

* Consistent in their evaluation, an analyst from Bernstein keeps a Market Perform rating on Lam Research ( LRCX ) with a target price of $85.

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.

If you want to stay updated on the latest options trades for Lam Research ( LRCX ), Benzinga Pro gives you real-time options trades alerts.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Carter's Fiscal Q3 Adjusted Earnings, Revenue Fall; Shares Down Pre-Bell
Carter's Fiscal Q3 Adjusted Earnings, Revenue Fall; Shares Down Pre-Bell
Oct 27, 2025
06:32 AM EDT, 10/27/2025 (MT Newswires) -- Carter's (CRI) reported fiscal Q3 adjusted earnings Monday of $0.74 per diluted share, down from $1.64 a year earlier. Analysts surveyed by FactSet expected $0.73. Revenue for the quarter ended Sept. 27 was $757.8 million, down from $758.5 million a year earlier. Analysts surveyed by FactSet expected $772.3 million. Additionally, the company said...
BRIEF-Sotherly Hotels To Be Acquired By Joint Venture Backed By Kemmons Wilson Hospitality Partners And Ascendant Capital Partners
BRIEF-Sotherly Hotels To Be Acquired By Joint Venture Backed By Kemmons Wilson Hospitality Partners And Ascendant Capital Partners
Oct 27, 2025
Oct 27 (Reuters) - Sotherly Hotels Inc ( SOHO ): * SOTHERLY HOTELS INC. ( SOHO ) TO BE ACQUIRED BY JOINT VENTURE BACKED BY KEMMONS WILSON HOSPITALITY PARTNERS AND ASCENDANT CAPITAL PARTNERS * SOTHERLY HOTELS INC ( SOHO ) - KW KINGFISHER TO BUY SOTHERLY SHARES FOR $2.25 PER SHARE * SOTHERLY HOTELS INC ( SOHO ) - APOLLO...
FireFly Notes Major High-Grade Copper and Gold Breakthrough at Green Bay Project
FireFly Notes Major High-Grade Copper and Gold Breakthrough at Green Bay Project
Oct 27, 2025
06:32 AM EDT, 10/27/2025 (MT Newswires) -- FireFly Metals ( MNXMF ) Monday released drilling results that point to a high-grade mineralized core over a strike length of at least 800 meters at the Green Bay copper-gold project in Canada, described by the company as a major exploration breakthrough. Highlights of the results include 43 m at 7.6% copper equivalent...
BridgeBio's genetic muscle disorder drug meets all goals in late-stage trial
BridgeBio's genetic muscle disorder drug meets all goals in late-stage trial
Oct 27, 2025
Oct 27 (Reuters) - BridgeBio Pharma ( BBIO ) said on Monday its experimental drug for a rare muscle disorder, which currently has no approved treatments, showed improvements in motor and lung function in a late-stage trial. The oral drug, BBP-418, is being tested in patients with a form of limb-girdle muscular dystrophy, or LGMD, a group of inherited genetic...
Copyright 2023-2026 - www.financetom.com All Rights Reserved